Clinical trial
Rectal Artery Infusion Chemotherapy of Oxaliplatin Plus Capecitabine Combined With Anti-PD1 Antibody After Induction Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer：a Prospective Single-arm Phase II Study
NCT05307198 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Rectal Artery Infusion Chemotherapy of Oxaliplatin Plus Capecitabine Combined With Anti-PD1 Antibody After Induction Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer：a Prospective Single-arm Phase II Study
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- May 11, 2022
- Completion date
- April 25, 2025
- Enrollment
- 38 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.